About Malecare

Malecare is the world's leading men's cancer support and advocacy nonprofit organization.

Caution- Do Not Combine Chemotherapy for Prostate Cancer with Avestin

An article appearing today the Urology Times E-News rang a warning bell about the use of the angiogenesis inhibitor bevacizumab (Avastin). The article warned that men with advanced prostate cancer may be at an increased risk of treatment-related death when bevacizumab is used in combination with other therapies. Senior author Shenhong Wu, MD, PhD, and [...]

The effect of PSA doubling time (PSADT) and Gleason score on the PSA at the time of initial metastasis in men with biochemical recurrence after prostatectomy.

The researchers took a cohort of 430 men with a biochemical recurrence (PSA increase only) after failed prostatectomy. The men underwent observation until they experienced metastatic disease as determined by CT or bone scan. The researchers then evaluated the PSA at the time the men developed metastasis for those patients who developed metastatic disease. PSA [...]

Pomegranate Effects PSADT in Men with Advanced Prostate Cancer

Prostate cancer diets and the use of supplements have continued to be an issue faced by men fighting advanced prostate cancer. Different products seem to fall in and out of vogue; unfortunately we usually have little actual hard data on the real value of any of these products. The use of pomegranate with the goal [...]

Surviving Chemotherapy by Stopping Unnecessary Infections

We have been having a lot of conversations on the advanced prostate cancer on-line group this last month about chemotherapy. Three of our advanced prostate cancer warriors have been openly sharing their experiences as they start docetaxel (taxotere or chemotherapy). Join the group at: Join the advanced prostate cancer on-line support group. It is important [...]

IxMP – A Potential Second or Third Line Chemotherapy- On The Horizon

Can IxMP Be Used as a Second or Third-Line Chemotherapy for Metastatic Castrate Resistant Prostate Cancer? There was a report recently released about a Phase 2 study from the Department of Defense funded Prostate Cancer Clinical Trials Consortium that suggests that ixabepilone + mitoxantrone + prednisone may have clinically significant activity as a form of [...]

Some Good News, The Funding for the DOD Prostate Cancer Program is On Track!

There is some good budgetary news as it now appears that the CDMRP (the Department of Defense) programs, including the Peer Reviewed Prostate Cancer Program, are funded at the omnibus level (last year’s level). The bill has not yet passed and is still vulnerable to changes. As of today, this is how the budget looks: [...]

Disease Risk, Not Age, Should Influence Prostate Cancer Treatment Decisions

Should treatments offered to older men with high risk prostate cancer be different than for younger men? Researchers from the University of California, San Francisco found that older men were denied more aggressive treatments because of their age. Men older than 75 years of age with high-risk prostate cancer often are under-treated when compared to [...]

One Large Step for Prostate Cancer and One Very Small Step for Men – Whole Genome Sequencing for Prostate Cancer

Yesterday the Prostate Cancer Foundation (PCRF) made a major announcement, it has sequenced the of whole cancer genomes of seven different men with aggressive prostate cancer. This is a historic development in the fight against prostate cancer, however, it is a small step for those of us on the ground. The eventual goal of projects [...]

One Man’s Experience Fighting The Side Effects of Jevtana (Cabaziltaxel)

A member of the advanced prostate cancer on-line group recently posted about his experience using the newly approved chemotherapy agent, Jevtana (cabazitaxel). His post included not only a report about his PSA response to the drug, but his experiences with side effects and a suggested method of controlling one of the debilitating side effect, diarrhea. [...]

Go to Top